Dr. Kyle A. Blum retweeted
Thank you Dr. Brian Donley, CEO of @nyphospital for visiting the Faltas Lab! We are building a leading #BladderCancer program at @nyphospital @WeillCornell, where science and research drive exceptional personalized patient care.
Well organized and informative symposium. Thank you to @mdstifelman @HUMCUrology and course faculty/staff for a great event. @WCMUrology
Amazing! 3 outstanding live cases:PNx,RALP &TV RASP moderated by an outstanding faculty. Great discussions with bright young minds,covering SP pearls across multiple procedures, including LAA SP RPLND.Fantastic education, collaboration..SP is present and future! @HUMCUrology
Dr. Kyle A. Blum retweeted
1/10 New in @JUOpenPlus: What drives vesicourethral anastomotic stenosis after contemporary robotic radical prostatectomy, and how should it be managed? In our @BNabavizadeh @nyphospital @GUUrology @KeithKow multicenter cohort of 1,591 men, we compared standard, Retzius-sparing, and hood RARP techniques. 🧵
Dr. Kyle A. Blum retweeted
Congratulations to Dr. Kyle Blum on his graduation from the Urologic Oncology Fellowship program!
Dr. Kyle A. Blum retweeted
Thank you @AmericanCancer for supporting our our research to advance treatments for patients with #BladderCancer at @FaltasLab @WCMGUcancer @WCMEnglanderIPM @WCM_MeyerCancer
bit.ly/4dWYzNW
Dr. Kyle A. Blum retweeted
Sarcomatoid diff in ccRCC is bad, but not super concordant between primary and matched metastasis.
This is a cool figure from @may_alley @katie_berry_MD showing discordance between metastasis (inner circle) and matched primary ccRCC (outer circle) in amount of sarcomatoid differentiation.
We know both metastasis and sarcomatoid diff are enriched for subclonal 9p loss, so you might expect more sarcomatoid in the met? but this does not appear to be always the case
mdpi.com/2077-0383/15/10/395…
Dr. Kyle A. Blum retweeted
What an amazing night at our annual alumni reception event!
We always have an incredible time seeing our @WeillCornell @nyphospital alumni and reconnecting with our colleagues and friends.
Looking forward to another great day at #AUA26 tomorrow!
Dr. Kyle A. Blum retweeted
In the EV era are we underusing local control?
🚩Among 459 patients with advanced urothelial carcinoma> just 108 received bladder-directed therapy after EV pub alert @CleClinicUro @UrolOncol
💡Cystectomy had the strongest survival signal in select pts supporting earlier multi D discussion @hjwang26 @MoningiShalini @AmandaNizamMD
Dr. Kyle A. Blum retweeted
In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%) and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years. Full phase 3 KEYNOTE-905/EV-303 trial results: nej.md/4czl8sG
Editorial: Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy nej.md/4twnv5T
ALT The Kaplan–Meier estimates of event-free survival as assessed by blinded independent central review in the intention-to-treat population, which included all participants who had undergone randomization.
Dr. Kyle A. Blum retweeted
#Tenure! I’m overwhelmed with gratitude to share that I’ve been awarded tenure at @WeillCornell @Cornell
I’m deeply grateful to my family, mentors, collaborators, and the many friends and colleagues in the field who have supported me in so many ways over the years. Too many names to list here! Thank you to every single one of you.
To the #FaltasLab members and alumni, your creativity, persistence, and teamwork made this possible. You’ve made me better in every way, and it’s a privilege to witness your growth and successes. This truly belongs to all of you.
As I reflect on this journey, I’m reminded of the challenges we’ve overcome, and of the profound privilege of being a physician-scientist: caring for patients with #bladdercancer, doing cutting-edge science, and mentoring the next generation of bright minds.
The next chapter is about asking bigger questions and building new bridges, between science and medicine, and between people! @WCMEnglanderIPM @WCM_MeyerCancer
With passion, persistence, and humility, onward!
Dr. Kyle A. Blum retweeted
Pelvic fascia‑sparing during RARP improves urinary continence recovery
🧬 Posterior PFS: 90% @3 mo, 96% @12 mo, 97% @20 mo
🧠 Anterior PFS: 83% @3 mo, 89% @12 mo, 99% @20 mo
🔬 Both techniques ~3.5‑fold ↑ continence at 3 mo; only posterior PFS sustained benefit at 20 mo
What is your preferred approach? Prospective data urgently needed…
doi.org/10.1016/j.euf.2025.0…
Dr. Kyle A. Blum retweeted
🎊 Abstract Submissions for #IKCSNA25 are Open! 🎊
Join the KCA on Nov 13-15 in Denver, CO for the 2025 IKCS: North America. Gather with top #kidneycancer experts to discuss and advance the field!
But first! Submit your abstracts and register: bit.ly/44tZSiH
Dr. Kyle A. Blum retweeted
Honored to be nominated to the Executive Committee of the Society for Basic Urologic Research @UrologySBUR!
If elected, I’ll work to expand the society’s scientific scope, enhance mentorship pathways, and foster collaborations that empower the next generation of investigators.
🗳️ VOTE NOW: sbur.memberclicks.net/2025-e…
🙏 Thank you for your support!
Dr. Kyle A. Blum retweeted
Last week @andyzwang & I published 1st of our translational research in #MolecularCancer @BioMedCentral, developing a multifunctional immunotherapy nanoparticle (MINP) to treat #kidneycancer. Thanks to #KinmanAu & #SiqingLi, 2 of our postdocs @utswcancer who did the work. 1/n
Dr. Kyle A. Blum retweeted
We are so proud of our residents for this honorable award!! 🏆
A remarkable accomplishment recognizing the continuous hard work of our residents and their numerous abstracts at #AUA25.
Congratulations to all!
Congratulations to the newly awarded 2025 National Residency Abstract Olympics winners! 🏆 @NM_Urology @wiscurology @WCMUrology
#AUA25
Dr. Kyle A. Blum retweeted
Apparently only smart people can see our poster. Just jk. Day1 #AUA25 Great chance to present RTIRE trial, especially honored to share research experience at World Chinese Urologic Society (WCUS). Thanks to all the mentors and of course I have the best co-residents. @WCMUrology
Dr. Kyle A. Blum retweeted
Great work @SanjanaR2024 @CarlosARiverosS Vatsala Mundra! @HMethodistUro @Yusuke_Tsugawa @DrNCoburn @propelresearch @ADetsky @WallisCJD
Patients who underwent surgery immediately preceding the weekend had an increased risk of complications, readmissions, and mortality compared with those treated after the weekend. ja.ma/41sb2CK
Dr. Kyle A. Blum retweeted
Welcome to @WCMGUcancer @rohitjainMD ! Excited to work with you to help more patients with #bladdercancer @IBCG_BladderCA @BladdCancerUS @WCMEnglanderIPM @WeillCornell
Sending out an official social media welcome to Dr. Rohit Jain (@rohitjainMD), the newest member of our #GU #cancer care team! He joined us at the end of 2024, caring for patients with #BladderCancer, #KidneyCancer, #ProstateCancer & #TesticularCancer: bit.ly/3Xokwhx
Dr. Kyle A. Blum retweeted
CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation
out on Clinical Cancer Research
aacrjournals.org/clincancerr…
This study explores potential biomarkers 🧬for early detection and disease monitoring of renal medullary carcinoma (RMC), a highly aggressive cancer primarily affecting young individuals of African descent with sickle cell trait🔬. Researchers performed integrated profiling of RMC tumor tissues and identified MUC16, the gene encoding cancer antigen 125 (CA-125), as significantly upregulated in RMC. Elevated serum CA-125 levels were observed in 66% of RMC patients and correlated with metastatic tumor burden. Functional studies demonstrated that restoring SMARCB1, a key tumor suppressor lost in RMC, reduced MUC16 expression.
These findings suggest that CA-125 could be a valuable biomarker for disease monitoring and treatment targeting in RMC. #KidneyCancer
@KyleBlumMD
@JPBertok
@DurgaNandTripat
@JustinLebenthal
@rahulshethmd
@priyaraomd
@LabGenovese
@lazcano_rossana
@ALazarMDPhD
@CCoarfa
@PavlosMsaouel
@OncoAlert 🚨
